Poisoned in the Womb: When Medicine's Mistakes Echo Through Generations - Jill Escher (#19)
Jill Escher's discovery that her mother received synthetic steroid hormones during pregnancy — and the possible link to surging rates of autism and gender dysphoria — carries uncomfortable echoes for Ireland. Irish women received similar drugs in the same era. As Stella O'Malley and her co-hosts explore with Escher, the silence of medical institutions on this question is a pattern Ireland knows all too well.
Jill Escher is a mother, autism advocate and president of the National Council on Severe Autism. Her search for an explanation for her two profoundly autistic sons led her to a revelation buried in medical records from 1965: her mother had received weekly injections of synthetic steroid hormones during pregnancy. What began as a personal mystery became a far larger question about what modern medicine has done to the developing brain — and whether it is willing to answer for it. The hormones Escher's mother received belong to a class of drugs that includes DES — diethylstilbestrol — a synthetic oestrogen prescribed to millions of pregnant women in the mid-twentieth century to prevent miscarriage. DES was eventually withdrawn after it was found to cause cancers and reproductive abnormalities in the daughters of women who took it. But Escher's work points to a further consequence: epigenetic disruption, where prenatal hormone exposure alters gene expression not just in the exposed child but potentially in subsequent generations. The damage, she argues, may be echoing through family lines in ways medicine has been slow to investigate. In this episode, Escher draws a connection between rising rates of autism and the surge in gender dysphoria, particularly among adolescents. She suggests these conditions may share a common thread in neurological vulnerability, rooted at least in part in what happened in the womb. For Stella O'Malley, a psychotherapist who has worked with gender-questioning young people in Ireland, this framing matters: it asks clinicians to look at the whole person, including their developmental history, rather than moving quickly towards social affirmation and medical intervention. The silence of institutions on this question is something Ireland understands well. From Thalidomide to symphysiotomy, from contaminated blood products to failures in cervical cancer screening, this country has a long record of medical establishments protecting themselves rather than the patients in their care. Escher describes the same pattern on a global scale: researchers who connect prenatal drug exposure to neurodevelopmental outcomes face institutional resistance, and families who need answers are left without them. Irish women were prescribed drugs in this class during the same decades Escher examines. Anti-miscarriage synthetic hormones remained available internationally — some variants until as recently as 2023 — and their long-term effects on subsequent generations have not been adequately studied. If Escher's hypothesis carries weight, the implications for Irish families, and for Irish children now presenting with autism or gender dysphoria, are significant. It would mean that some of what clinicians are encountering in consulting rooms and gender clinics has its roots in obstetric decisions made a generation or two ago. What Escher and the Beyond Gender hosts call for is not alarm but honesty: rigorous research, open conversation, and the scientific courage to follow evidence wherever it leads. For Irish healthcare, where the debate around gender-questioning youth is already politically charged and clinically contested, adding this biological dimension feels both necessary and long overdue.
